Massachusetts Society of Clinical Oncologists - FDA Broadens Indication and Grants Expanded Approval for Established RET-Targeted Therapy

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
For Professionals
Drug Updates
FDA Broadens Indication and Grants Expanded Approval for Established RET-Targeted Therapy

FDA Broadens Indication and Grants Expanded Approval for Established RET-Targeted Therapy

11 Oct 2022 10:36 AM | Katy Monaco (Administrator)

Lilly USA, LLC is pleased to announce recent major label changes for Retevmo^® (selpercatinib, 80 mg and 40 mg capsules). Read press release here.

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: msco@mms.org